Mepolizumab Reduces Flares in Patients With Hypereosinophilic Syndrome
GSK announced positive results from the pivotal phase 3 study of mepolizumab in the treatment of patients with hypereosinophilic syndrome.
Allergies
Dupilumab May Lower Exacerbation Rates in Allergic Bronchopulmonary Aspergillosis
In a post hoc analysis of the LIBERTY ASTHMA QUEST study, researchers found that dupilumab may reduce exacerbations in patients with allergic bronchopulmonary aspergillosis.
Sesame-Specific IgE Levels May Help Diagnose Allergy
Sesame allergy affects 17 percent of children with IgE-mediated food allergy.
Ragweed SLIT Tablet Improves Symptoms in Children With Ragweed Allergic Rhinitis
Ragweed sublingual immunotherapy tablet improved symptoms and decreased the need for rescue medication in the largest allergy immunotherapy trial in children with ragweed allergic rhinitis with or without conjunctivitis.
High-Dose Peanut Oral Immunotherapy Safe, Effective for Peanut Allergy
High-dose peanut oral immunotherapy provided similar or greater efficacy than other previously reported forms of peanut oral immunotherapy without additional safety concerns.
Pediatric Asthma Plus Atopic Dermatitis Associated With Poor Sleep Outcomes
Asthma plus atopic dermatitis may lead to poorer sleep-specific outcomes in pediatric patients.
AR101 Demonstrates Safety and Efficacy in Peanut Oral Immunotherapy
The oral biologic drug AR101 has demonstrated consistent efficacy and safety in providing oral peanut immunotherapy to patients with peanut allergy and sensitization.
Diet Diversity in Pregnancy Lowers Risk of Offspring Eczema and Allergy
A diverse maternal diet during pregnancy, especially among mothers who have a history of allergic disease, is associated with lower rates of eczema and/or food allergies in infant offspring.
What Is the Psychosocial Effect of Food Allergies?
A population-based survey found that adverse quality of life due to food allergies was more common among individuals in lower income brackets and in younger age groups, as well as in those with greater education.
BCX7353 Reduced Hereditary Angioedema Attacks Over 24 Weeks
The oral plasma kallikrein inhibitor, BCX7353, reduced hereditary angioedema attacks during a 24-week treatment period.
Next post in ACAAI 2019
